disruption, yet the impact of virus replication and immune cell recruitment on BBB integrity are incompletely understood. Using two-photon microscopy, we demonstrate that Venezuelan equine encephalitis virus (VEEV) strain TC83-GFP, a GFP expressing, attenuated strain with a G3A mutation within the 5′ UTR that is associated with increased sensitivity to type I interferons (IFNs), does not directly impact BBB permeability. Following intranasal infection of both wild-type and IFN-induced protein with tetratricopeptide repeats 1 (IFIT1)-deficient mice, which fail to block TC83-specific RNA translation, virus spreads to the olfactory bulb and cortex via migration along axonal tracts of neurons originating from the olfactory neuroepithelium. Global dissemination of virus in the CNS by 2 days post-infection (dpi) was associated with increased BBB permeability in the olfactory bulb, but not in the cortex or hindbrain, where permeability only increased after the recruitment of CX3CR1 + and CCR2
Introduction
Venezuelan equine encephalitis virus (VEEV) is a member of the Togaviridae family of positive-sense RNA alphaviruses, and naturally cycles between mosquitoes and rodents (enzootic cycle), or mosquitoes and horses (epizootic cycle) (Salimi et al., 2016) . VEEV is considered an important zoonotic pathogen with several reported outbreaks in South and Central Americas, the latter of which have spread to North America (Morrison et al., 2008; Weaver et al., 1996) . Natural or laboratoryacquired infections have been documented in humans with all epizootic and many enzootic VEEV strains. After a 1 to 6 day incubation period, patients develop high fever, headache, malaise, and myalgia. The case fatality rate is < 1%, but can be as high as 20% in patients that develop encephalitis. Although the number of human cases reported is small, the possibility for disease emergence is high due to expansion and spread of mosquito vectors. Furthermore, VEEV can also be spread via aerosolization and thus has significant potential as a bioterrorist agent (Sergeev et al., 1991) . Currently, there are no FDA-approved antiviral agents or vaccines to mitigate or prevent VEEV encephalitis. Moreover, our understanding of the mechanisms of VEEV neuroinvasion and virologic control within the central nervous system (CNS) are incompletely understood.
The CNS is normally protected from pathogens by the blood brain barrier (BBB), an anatomical specialization composed of tight junction (TJ)-linked brain microvascular endothelial cells (BMECs), associated pericytes, astrocyte end-feet and extracellular matrix. In previous studies, we have demonstrated that barrier function during neurotropic viral infections is dynamic and that viral sensing by BMECs may improve BBB integrity via mechanisms in which TAM receptor Mertk and the IFN receptor (IFNAR) synergistically impact on the activity of Rac1, a RhoGTPase family member that promotes TJ stabilization, while inhibiting the expression of interleukin (IL)-1, a barrier destabi-
